Sigma Labs Inc (SASI)

[GetRich1day]

Silver, Onvo has been my case study; thus, I personally think that it is fairly relevant. There are a number of comparisons such as being
1) Being a 3D play
2) Being listed in OTC
3) Doing a reverse split
4) S-1 filing
5) dilution of shares
6) Being a company with a ton of potential but no significant revenues yet

I've mentioned before that SGLB is following a very similar path to uplist.

They did a private placement on the OTC to raise funds just like SGLB did.

The company says it raised total gross proceeds of $6.5 million through a private placement of its securities to qualified investors. Organovo had previously raised about $3 million in debt financing that could be converted to Organovo shares.

http://www.xconomy.com/san-diego/2012/02/14/organovo-raises-6-5m-lists-on-otc-in-alternative-public-offering/#

They got the same kind of bashing that SGLB recieved on their way up.

The obviously overvalued penny stock of Organovo Holdings Inc. (ONVO) had their 2nd largest volume trading session Thursday for all the wrong reasons. ONVO stock price rose to as high as $4.50 after falling from their prior Seeking Alpha PR pump high of $10.90 after some of the truths already available to the public were exposed. We are willing to go even further to state that ONVO, not only will be at $1 before the end of July, but that it will fall below $1 soon after. Why?

http://www.aimhighprofits.com/what-will-traders-do-when-organovo-holdings-onvo-is-1-14976

I bet that SGLB will have a similar announcement in 2 to 3 months!

SAN DIEGO, July 9, 2013 /PRNewswire/ — Organovo Holdings, Inc. (ONVO), a biotechnology company focused on delivering breakthrough three-dimensional (3D) bioprinting technology, is pleased to announce that its common shares have been approved to list on the NYSE MKT and will begin trading on the New York Stock Exchange on July 11, 2013. The Company will continue to trade under the symbol “ONVO” but will withdraw its shares from listing on the OTC QX concurrent with listing its shares on the NYSE MKT, the premier US equities market for listing and trading of small growth companies.

https://3dprintingstocks.com/organovo-onvo-is-uplisting/

ONVO has a ton of potential but no significant revenues.

The company’s flagship commercial product is the exVive 3D Human Liver Assays and although management has decided not to reveal information on its sales until later this year, there is no doubt that the potential market is massive. Also, Organovo won’t be banking on this product alone as it plans to develop a kidney which will command higher prices compared to the liver. With the increased visibility of a national listing, the company will be able to raise capital to fund subsequent trials at more favourable terms.

http://wealthyventurecapitalist.com/2016/06/14/these-companies-prove-that-reverse-splits-can-be-a-very-good-thing-for-stakeholders/

I think just like you that the uplisting to the NASDAQ will deliver a pop to the pps as the big boys will be able to play. Should a major contract announcement come then SGLB is off to the races!! GLTU
dot + dot + dot = Success!!